journal article·2024-02

Self‐Reliant Nanomedicine with Long‐Lasting Glutathione Depletion Ability Disrupts Adaptive Redox Homeostasis and Suppresses Cancer Stem Cells

Yuxuan Xiong, Zhengtao Yong, Shiyou Li, Qiang Wang, Xiang Chen, Zhijie Zhang, Qingfu Zhao, Qingyuan Deng, Xiangliang Yang, Zifu Li

Advanced Functional Materials· Volume 34· Issue 8
Publisher page

Abstract

Abstract Bulk cancer cells and cancer stem cells (CSCs) harbor efficient and adaptive redox systems to help them resist oxidative insults arising from diverse therapeutic modalities. Herein, a tumor microenvironment (TME)‐activatable nano‐modulator capable of disrupting adaptive redox homeostasis, prepared by integrating FDA‐approved xCT inhibitor sulfasalazine (SSZ) into pH‐responsive hydroxyethyl starch‐doxorubicin conjugate stabilized copper peroxide nanoparticles (HSCPs) is reported. Compared to poly(vinylpyrrolidone) (PVP)‐stabilized copper peroxide nanoparticles, HSCPs exhibit superior physiological stability, longer circulation half‐life, and higher tumor enrichment. Under an acidic TME, the active components inside HSCPs are productively released along with the disintegration of HSCPs. The specifically generated hydrogen peroxide (H2O2) from copper peroxide nanoparticles furnishes a constant power source for copper‐mediated hydroxyl radical (•OH) production, serving as a wealthy supplier for oxidative stress. Meanwhile, the tumor‐specific release of Cu2+ and SSZ can induce long‐lasting glutathione (GSH) depletion via copper‐mediated self‐cycling valence transitions and SSZ‐blocked GSH biosynthesis, thereby reducing the offsetting action of the antioxidant GSH against oxidative stress. As a result, this sustained oxidative stress potently restrains the growth of aggressive orthotopic breast tumors while suppressing pulmonary metastasis by eradicating CSC populations. The reported smart nanomedicine provides a new paradigm for redox imbalance‐triggered cancer therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Sulfur Compounds in Biology · Advanced Nanomaterials in Catalysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

National Engineering Research Center for Nanomedicine College of Life Science and Technology Huazhong University of Science and Technology Wuhan 430074 P. R. China

Key Laboratory of Molecular Biophysics of Ministry of Education College of Life Science and Technology Huazhong University of Science and Technology Wuhan 430074 P. R. China

Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medical Huazhong University of Science and Technology Wuhan 430074 P. R. China

Hubei Engineering Research Center for Biomaterials and Medical Protective Materials Huazhong University of Science and Technology Wuhan 430074 P. R. China

Hubei Bioinformatics and Molecular Imaging Key Laboratory College of Life Science and Technology Huazhong University of Science and Technology Wuhan 430074 P. R. China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Huazhong University of Science and Technology

References (62)

Show source-provided references
1. 10.1016/j.drup.2004.01.00410.1016/j.drup.2004.01.004 ↗
2. 10.1016/j.canlet.2015.07.00810.1016/j.canlet.2015.07.008 ↗
3. 10.1039/D0CS00718H10.1039/D0CS00718H ↗
4. 10.1016/j.redox.2020.10175310.1016/j.redox.2020.101753 ↗
5. 10.1038/nature0773310.1038/nature07733 ↗
6. 10.1089/ars.2012.452910.1089/ars.2012.4529 ↗
7. 10.1016/j.semradonc.2018.10.00310.1016/j.semradonc.2018.10.003 ↗
8. 10.1002/jbt.2294210.1002/jbt.22942 ↗
9. 10.1155/2013/71985810.1155/2013/719858 ↗
10. 10.1097/MCO.000000000000013410.1097/MCO.0000000000000134 ↗
11. 10.4161/oxim.2.5.944110.4161/oxim.2.5.9441 ↗
12. 10.1007/s00204-015-1579-510.1007/s00204-015-1579-5 ↗
13. 10.1021/jacs.1c1185610.1021/jacs.1c11856 ↗
14. 10.1002/anie.20180566410.1002/anie.201805664 ↗
15. 10.1002/anie.20221041510.1002/anie.202210415 ↗
16. 10.1080/1040836050052387810.1080/10408360500523878 ↗
17. 10.1021/acs.nanolett.9b0290410.1021/acs.nanolett.9b02904 ↗
18. 10.1002/adma.20220628610.1002/adma.202206286 ↗
19. 10.1021/acsnano.0c0549910.1021/acsnano.0c05499 ↗
20. 10.1016/j.chempr.2020.02.02010.1016/j.chempr.2020.02.020 ↗
21. 10.1016/0006-291X(69)90850-X10.1016/0006-291X(69)90850-X ↗
22. 10.1152/ajpgi.1998.275.4.G74910.1152/ajpgi.1998.275.4.G749 ↗
23. 10.1007/BF0179535410.1007/BF01795354 ↗
24. 10.1038/sj.leu.240223810.1038/sj.leu.2402238 ↗
25. 10.1200/jco.2014.32.15_suppl.254510.1200/jco.2014.32.15_suppl.2545 ↗
26. 10.1111/cas.1396010.1111/cas.13960 ↗
27. 10.1186/s13046-017-0511-710.1186/s13046-017-0511-7 ↗
28. 10.1073/pnas.142101811210.1073/pnas.1421018112 ↗
29. 10.1021/acs.nanolett.9b0276910.1021/acs.nanolett.9b02769 ↗
30. 10.1021/jacs.9b0345710.1021/jacs.9b03457 ↗
31. 10.7150/thno.6757210.7150/thno.67572 ↗
32. 10.1016/j.cej.2018.05.08210.1016/j.cej.2018.05.082 ↗
33. 10.1002/advs.20230127810.1002/advs.202301278 ↗
34. 10.1021/jp203799m10.1021/jp203799m ↗
35. Honary S. · Trop. J. Pharm. Res. · 2013 · 12 · 255
36. 10.1016/j.molstruc.2020.12815810.1016/j.molstruc.2020.128158 ↗
37. 10.1021/acsnano.9b0209610.1021/acsnano.9b02096 ↗
38. 10.1016/j.actbio.2016.02.00510.1016/j.actbio.2016.02.005 ↗
39. 10.1016/j.canlet.2015.07.03110.1016/j.canlet.2015.07.031 ↗
40. 10.1021/jacs.8b0871410.1021/jacs.8b08714 ↗
41. 10.1126/sciadv.aax134610.1126/sciadv.aax1346 ↗
42. 10.3390/ijms16051108710.3390/ijms160511087 ↗
43. 10.1002/anie.20160550910.1002/anie.201605509 ↗
44. 10.1038/onc.2015.6010.1038/onc.2015.60 ↗
45. 10.1186/1471-2407-6-26710.1186/1471-2407-6-267 ↗
46. 10.1084/jem.153.3.72010.1084/jem.153.3.720 ↗
47. 10.1152/jappl.1985.58.2.57110.1152/jappl.1985.58.2.571 ↗
48. 10.1016/j.pharmthera.2013.09.00610.1016/j.pharmthera.2013.09.006 ↗
49. 10.1016/j.ccell.2019.04.00210.1016/j.ccell.2019.04.002 ↗
50. Ksiezakowska‐Lakoma K. · Prz Menopauzalny · 2014 · 13 · 136
51. 10.1016/0076-6879(95)60154-610.1016/0076-6879(95)60154-6 ↗
52. 10.3389/fonc.2013.0029210.3389/fonc.2013.00292 ↗
53. 10.1038/s41392-020-0110-510.1038/s41392-020-0110-5 ↗
54. 10.1021/acs.accounts.1c0063510.1021/acs.accounts.1c00635 ↗
55. 10.1016/j.cmet.2018.06.00610.1016/j.cmet.2018.06.006 ↗
56. 10.1038/s41551-019-0405-410.1038/s41551-019-0405-4 ↗
57. 10.1016/j.biocel.2011.12.02010.1016/j.biocel.2011.12.020 ↗
58. 10.1021/acsami.6b1193210.1021/acsami.6b11932 ↗
59. 10.2165/00003088-200544070-0000210.2165/00003088-200544070-00002 ↗
60. 10.2217/nnm.16.510.2217/nnm.16.5 ↗
61. 10.1038/nm146910.1038/nm1469 ↗
62. 10.1038/s41419-018-1094-810.1038/s41419-018-1094-8 ↗